Movement Alert｜Hims & Hers Health Falls 5.73% in Regular Trading, GLP-1 Transition Costs and Analyst Downgrade Weigh on Shares

Market Focus06-12

On June 12, Hims & Hers Health declined 5.73% in regular trading, trading at $27.163/share, with turnover of $59.13 million. The decline reflects ongoing pressure from multiple headwinds including an analyst target price cut and deteriorating fundamentals.

Bank of America recently lowered its price target on the company to $25, further undermining bullish sentiment. The stock continues to face selling pressure as the company strategically transitions toward selling branded GLP-1 drugs rather than compounded versions, a shift that is driving up costs and compressing profit margins. Additionally, the company reported a first-quarter net loss of $92.115 million, or -$0.40 per share, representing a 286.15% year-over-year decline from profitability to loss, with revenue of $608 million growing only 3.77% year-over-year. Concerns over potential FDA tightening of compounded drug regulations also remain an overhang.

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals, enabling access to medical care for mental health, sexual health, dermatology and primary care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111544967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111544967","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Falls 5.73% in Regular Trading, GLP-1 Transition Costs and Analyst Downgrade Weigh on Shares","media":"Market Focus","content":"<p><p>On June 12, Hims & Hers Health declined 5.73% in regular trading, trading at $27.163/share, with turnover of $59.13 million. The decline reflects ongoing pressure from multiple headwinds including an analyst target price cut and deteriorating fundamentals.</p><p>Bank of America recently lowered its price target on the company to $25, further undermining bullish sentiment. The stock continues to face selling pressure as the company strategically transitions toward selling branded GLP-1 drugs rather than compounded versions, a shift that is driving up costs and compressing profit margins. Additionally, the company reported a first-quarter net loss of $92.115 million, or -$0.40 per share, representing a 286.15% year-over-year decline from profitability to loss, with revenue of $608 million growing only 3.77% year-over-year. Concerns over potential FDA tightening of compounded drug regulations also remain an overhang.</p><p>Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals, enabling access to medical care for mental health, sexual health, dermatology and primary care.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Falls 5.73% in Regular Trading, GLP-1 Transition Costs and Analyst Downgrade Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Falls 5.73% in Regular Trading, GLP-1 Transition Costs and Analyst Downgrade Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Hims & Hers Health declined 5.73% in regular trading, trading at $27.163/share, with turnover of $59.13 million. The decline reflects ongoing pressure from multiple headwinds including an analyst target price cut and deteriorating fundamentals.</p><p>Bank of America recently lowered its price target on the company to $25, further undermining bullish sentiment. The stock continues to face selling pressure as the company strategically transitions toward selling branded GLP-1 drugs rather than compounded versions, a shift that is driving up costs and compressing profit margins. Additionally, the company reported a first-quarter net loss of $92.115 million, or -$0.40 per share, representing a 286.15% year-over-year decline from profitability to loss, with revenue of $608 million growing only 3.77% year-over-year. Concerns over potential FDA tightening of compounded drug regulations also remain an overhang.</p><p>Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals, enabling access to medical care for mental health, sexual health, dermatology and primary care.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1111544967","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111544967","pubTimestamp":1781272028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Hims & Hers Health declined 5.73% in regular trading, trading at $27.163/share, with turnover of $59.13 million. The decline reflects ongoing pressure from multiple headwinds including an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"动向警报|Hims&Hers Health在常规交易中下跌5.73%，GLP-1过渡成本和分析师评级下调令股价承压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On June 12, Hims & Hers Health declined 5.73% in regular trading, trading at $27.163/share, with turnover of $59.13 million. The decline reflects ongoing pressure from multiple headwinds including an analyst target price cut and deteriorating fundamentals.Bank of America recently lowered its price target on the company to $25, further undermining bullish sentiment. The stock continues to face selling pressure as the company strategically transitions toward selling branded GLP-1 drugs rather than compounded versions, a shift that is driving up costs and compressing profit margins. Additionally, the company reported a first-quarter net loss of $92.115 million, or -$0.40 per share, representing a 286.15% year-over-year decline from profitability to loss, with revenue of $608 million growing only 3.77% year-over-year. Concerns over potential FDA tightening of compounded drug regulations also remain an overhang.Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals, enabling access to medical care for mental health, sexual health, dermatology and primary care.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111544967","isCrawlerRequest":true}